Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Titel:
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Auteur:
Motzer, Robert J Escudier, Bernard Tomczak, Piotr Hutson, Thomas E Michaelson, M Dror Negrier, Sylvie Oudard, Stephane Gore, Martin E Tarazi, Jamal Hariharan, Subramanian Chen, Connie Rosbrook, Brad Kim, Sinil Rini, Brian I